"Oisín Biotechnologies Raises $15M for Age-Related Disease Therapies"
Oisín Biotechnologies Holds First Close of $15M Series A Financing
Oisín Biotechnologies raises $15M in Series A Funding
Oisín Biotechnologies (Linkedin), a leader in genetic medicine for age-related diseases, secured $15M in Series A funding. With AbbVie Ventures as the lead investor, Oisín is poised to revolutionize the treatment of age-related diseases and improve the lives of millions.
Funding Amount: $15 million
Industry: Biotechnology Research
Employee Count: 11-50
CEO: Matthew Scholz (CEO Linkedin)
What Oisín Biotechnologies needs to buy: Oisín Biotechnologies is seeking partnerships with biotech companies, research institutions, clinical trial service providers, and manufacturers. These collaborations will enable Oisín to advance their therapies, conduct clinical trials, and ensure efficient manufacturing and supply chain management for their genetic medicines. Companies specializing in genetic medicine, clinical trial services, and manufacturing solutions should consider partnering with Oisín Biotechnologies to drive innovation in age-related disease treatment.